Back

Role of NTproBNP and donor-derived cell-free DNA in the diagnosis of acute rejection in heart transplant recipients: a prospective study

25 August 2023 (15:40 - 15:50)
Organised by: Logo
Congress Presentation Part of: Challenges and opportunities in heart transplantation and ventricular assist devices Heart Transplantation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Marta Jimenez-Blanco Bravo

Ramon and Cajal University Hospital, Madrid (Spain)

5 More presentations in this session

Presentation thumbnail
Non-HLA autoantibodies supplement donor specific antibodies in predicting graft survival after heart transplantation
Doctor G. Oh (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Urinary proteomics signature of malignancy post heart transplantation is associated with mortality risk
Doctor Z. Zhang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Transcatheter edge to edge repair of functional mitral regurgitation as bridge to heart transplantation: 2-years follow up results from MitraBridge international registry
Doctor C. Marcelli (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Transition from temporary microaxial left ventricular assist devices to durable mechanical circulatory support systems
Mr D. Lewin (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Bridging therapy and risk of major bleeding and thrombosis in continuous-flow left ventricular assist device patients: a quasi-experimental study
Mr R. Roovers (Leiden, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Challenges and opportunities in heart transplantation and ventricular assist devices
Video

The Event

Event poster

ESC Congress 2023

25 August 2023 15:40 CET
You may be interested in
thumbnail
Congress Presentation
Decentralized donor-derived cell-free DNA testing for cardiac allograft rejection: clinical validation and additive value beyond standard-of-care monitoring
thumbnail
Congress Presentation
Donor-derived cell-free DNA as a new biomarker for acute rejection in heart transplant recipients: results from the freedna car study
thumbnail
Congress Presentation
Donor-derived cell-free DNA versus left ventricular global longitudinal strain in noninvasive detection of heart allograft injury